Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacotherapy in the USA. However, the molecular and cellular mechanisms underlying which intermittent PTH stimulates bone formation are not fully established.
Introduction
Osteoporotic fracture is estimated to occur every 3 s worldwide [1] . Osteoporosis is a disease characterized by low bone mass and deterioration in the microarchitecture of bone tissue [2] . Currently, the only available anabolic agent in clinical use for the treatment of osteoporosis in USA is PTH. Intermittent administration of PTH peptide 1-34 or full-length protein PTH 1-84 increases bone formation in osteoporotic patients [3] . However, the molecular and cellular mechanisms underlying which intermittent PTH stimulates bone formation are not fully established.
Our previous studies demonstrate that anabolic action of PTH on bone formation requires FGF2. PTH increases FGF2 and FGF receptor mRNA expression in cultured osteoblasts [4] . Furthermore, PTH treatment increases serum FGF2 and increases bone formation markers in osteoporotic patients [5] . However disruption of FGF2 gene in mice results in dramatic reduction in bone formation [6] , suggesting the importance of endogenous FGF2 in bone formation. Moreover, in Fgf2 −/− mice, PTH has impaired ability to stimulate bone formation [7] . These studies indicate that FGF2 is required for PTH to stimulate bone formation.
Bone formation is mediated by osteoblasts. Osteoblast differentiation from bone marrow stromal cell is governed by transcription factors, including Runx2 and ATF4 [8] . ATF4 is critical for osteoblast terminal differentiation and for maintaining mature osteoblast function including synthesizing collagen and osteocalcin [9] . Osteocalcin is one transcriptional target of ATF4 in osteoblasts [9] . The requirement of ATF4 in osteoblast differentiation is revealed by ATF4 knock out mice. Atf4 −/− mice display a dramatic decrease in osteocalcin expression together with severe reduction of bone mass and bone formation [9] . In contrast, ATF4 overexpression increases osteocalcin expression in osteoblasts [10] . These studies suggest that ATF4 is a transcriptional activator required for osteoblast terminal differentiation and osteocalcin expression.
ATF4 has recently been identified as a novel downstream target gene of PTH signaling in osteoblasts [11, 12] . PTH induces ATF4 mRNA/protein expression and increases ATF4 transcriptional activity in MC3T3-E4 cells and in BMSCs [11] . But PTH could not induce osteocalcin expression in ATF4 knockdown MC3T3-E4 cells or in Atf4 −/− BMSCs [11] . Moreover, the anabolic actions of PTH in bone was severely impaired in Atf4 −/− mice [12] .
These results suggest that bone formation stimulated by PTH is in part mediated by ATF4.
We recently reported that ATF4 expression is regulated by FGF2 in osteoblasts. FGF2 is able to rapidly increase ATF4 mRNA and protein expression in osteoblasts [13] . Furthermore, ATF4 expression is markedly reduced in Fgf2 −/− osteoblasts [13] . Therefore, we hypothesize that the impaired anabolic effect of PTH in Fgf2 −/− mice is partially due to reduced ATF4 expression. To test this hypothesis, we examined the ability of PTH to increase ATF4 expression both in vitro and in vivo.
In this study, we provide evidence that PTH is not able to induce ATF4 mRNA expression in the absence of FGF2 in BMSCs in vitro and PTH in vivo treatment increased ATF4 mRNA expression in tibia and ATF4 protein expression in vertebrae tissue is attenuated in FGF2 knockout mice. These results suggest that the impaired bone response to PTH in Fgf2 −/− mice is in part due to reduced ATF4 expression.
Materials and methods

Animals
Fgf2 knockout mice were previously developed on a black swiss 129Sv background [14] .
Mice used in this study were on a new mix genetic background of black swiss 129Sv/FVB/ N. Genotyping of mice was performed using primers as previously described [14, 15] . Mice were bred and housed in the transgenic facility in the center for laboratory animal care at the University of Connecticut Health Center. Mice were sacrificed by CO 2 narcosis and cervical dislocation. The Animal Care and Use Committee of the University of Connecticut Health Center approved all animal protocols.
Littermates of male or female mice were utilized as indicated in the figure legends. For PTH injection experiments, two independent studies were done using 17-19 month old mice (n = 3-4/group) or 21-23 month-old female mice (n = 2-3/group) that were weighed and injected subcutaneously with vehicle (0.001 M HCl in PBS with 1 mg/ml BSA) (n = 2-3) or 40 μg/ kg human PTH (1-34) (Bachem, Torrence, CA, USA) 5×/week for 2 weeks. Two days after the last injection of PTH, in vivo vertebral BMD and BMC were determined, and then the third vertebrae were placed in 10% phosphate-buffered formalin for 48 h and subsequently stored in 70% ethanol before immunohistochemistry staining. Left tibia were dissected and cut off the epiphyses for RNA extraction.
Bone mineral density (BMD) and bone mineral content (BMC)
In vivo vertebral BMD and BMC were determined using dual energy X-ray absorptiometry (DXA; PIXimus mouse 11 densitometer, GE Medical System, Madison WI).
RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from cells with TRIzol reagent (Invitrogen, CA, USA) according to the manufacture's protocol. RNA (3 μg) was reverse transcribed using a commercial kit (Clontech, CA, USA). Quantitative real-time PCR (qPCR) was carried out using the QuantiTect™ SYBR Green PCR kit using a MyiQ™ instrument (Bio-Rad, Laboratories Inc. Hercules, CA, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal reference for each sample. Relative mRNA expression was calculated using a formula reported previously [16] . The mouse specific primers are as follows: Gapdh, 5′-CAG TGC CAG CCTCGT CCC GTA GA-3′ (forward), 5′-CTG CAA ATG GCA GCC CTGGTG AC-3′ (reverse); osteocalcin, 5′-GAG GGC AAT AAG GTA GTG AAC AGA-3′ (forward), 5′-AAG CCA TAC TGG TTT GAT AGC TCG-3′ (reverse); Type I collagen (col1a1), 5′-GGT CCT CGT GGT GCT GCT-3′ (forward), 5′-ACC TTT GCC CCC TTC TTT G-3′ (reverse); Atf4, 5′ -GAG CTT CCT GAA CAG CGA AGT G-3′ (forward), 5′ -TGG CCA CCT CCA GAT AGT CAT C-3′ (reverse).
Immunohistochemistry staining
For histological analysis, vertebrae samples incubated in 70% ethanol were decalcified in 20% EDTA in PBS for 7 days at room temperature and paraffin blocks were prepared by standard procedures. Samples were then cut into 5 μm sections. Sections were deparaffinized and stained with ATF4 antibody (1:50, Santa Cruz, CA, USA) using ABC staining system (Santa Cruz, CA, USA) following the product protocol.
Bone marrow stromal cell cultures
For PTH in vitro treatment experiments, BMSC-isolation was described previously [13] . Briefly, femurs and tibiae from Fgf2 +/+ and Fgf2 −/− mice were dissected and both epiphyses were removed, then bones were centrifuged briefly in eppendorf tubes to release bone marrow cells. The marrow cells were plated at 10 × 10 6 cells/well in six-well plates in α -MEM (Gibco-BRL, Grand Island, New York, USA) containing 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (50 μg/ml). To study whether exogenous PTH promoted ATF4 expression, the cells had half medium changed on day 3 and the entire medium changed on day 6 with FBS-free α-MEM, with serum deprivation 14 h before adding exogenous 1 nM PTH or vehicle for 15 min, 30 min, 1 h, 3 h, or 6 h. Then cells were harvest for RNA extraction and gene analysis as describe above.
Statistical analysis
Results were expressed as the means ± SEM. Differences between wild type vs knockout or vehicle vs treatment were analyzed using a student's t-test, and differences were considered significant at p < 0.05.
Results
PTH is not able to increase ATF4 mRNA expression in the absence of endogenous FGF2 in BMSCs in vitro
The ability of PTH to increase ATF4 expression was first examined in BMSCs. As shown in Fig. 1, ATF4 mRNA expression is significantly reduced in Fgf2 −/− BMSCs compared to Fgf2 +/+ BMSCs at basal level. PTH treatment significantly increased ATF4 mRNA expression in Fgf2 +/+ BMSCs as early as 15 min. However, PTH was not able to increase ATF4 mRNA expression in Fgf2 −/− BMSCs at all the time points examined.
Anabolic action of PTH on bone formation is impaired in Fgf2 −/− mice compared to wild type littermates
We next assessed bone formation stimulated by PTH in 21-23 month-old female mice on a black swiss 129Sv/FVB/N genetic background. We observed that PTH treatment increased lumbar vertebrae BMD in Fgf2 +/+ mice with a 13.8% increase. In contrast there was a 2.1% decrease in Fgf2 −/− mice ( Fig. 2A) . PTH treatment increased lumbar vertebrae BMC with a 19.8% increase in Fgf2 +/+ mice but there was a 9.9% decrease in Fgf2 −/− mice (Fig. 2B) .
We also examined genes that are important for osteoblasts differentiation using RNA extracted from tibiae after PTH in vivo administration. For Col1a1 mRNA expression (Fig.  2C ), PTH induced a 363% increase in Fgf2 +/+ mice vs a 118% in Fgf2 −/− mice. As shown in (Fig. 2D) , PTH induced a 221% increase in osteocalcin expression in Fgf2 +/+ mice vs 173% in Fgf2 −/− mice. Also (Fig. 2E) , PTH injection induced a 51% increase in Runx2 mRNA expression in Fgf2 +/+ mice vs 10% in Fgf2 −/− mice. These data showed that increased gene expression of osteocalcin, Col1a1 and Runx2 stimulated by PTH injection were attenuated in Fgf2 −/− mice compared to Fgf2 +/+ mice. Impaired bone anabolic response to PTH was also seen in 17-19 month-old female mice with 16.9% increase in vertebrae BMD in Fgf2 +/+ mice vs 6.2% increase in Fgf2 −/− mice.
Increased ATF4 mRNA and protein expression by PTH injection is attenuated in Fgf2 −/− mice compared to wild type littermates
Since the anabolic action of PTH on bone formation requires ATF4, we investigated the ability of PTH to increase ATF4 expression in vivo in 21-23 month old female Fgf2 −/− mice compared to wild type littermates. Interestingly, ATF4 mRNA expression in tibiae was significantly lower in Fgf2 −/− mice (a 46% decrease) compared to Fgf2 +/+ mice. PTH treatment increased ATF4 mRNA expression by 97% (p < 0.05) in Fgf2 +/+ compared to 8% (p = 0.57) in Fgf2 −/− mice, as shown in Fig. 3A .
We further examined ATF4 protein in vivo expression by immunohistochemistry on lumbar vertebrae after PTH injection. As shown in Fig. 3B , there was less ATF4 staining in Fgf2 −/− vertebrae tissue, particularly in osteoblast cells lining the bone surface (arrow) compared to Fgf2 +/+ tissue, and treatment with PTH increased ATF4 staining in Fgf2 +/+ but the increase was attenuated in Fgf2 −/− tissue.
Discussion
In the present study, we found that PTH did not increase ATF4 mRNA expression in the absence of endogenous FGF2 in BMSCs in vitro. Furthermore, increased ATF4 mRNA in tibia and ATF4 protein expression in vertebrae tissue by PTH injection is attenuated in Fgf2 −/− mice compared to wild type littermates. Attenuated ATF4 expression may contribute to the impaired anabolic actions of PTH on bone formation in Fgf2 −/− mice.
The impaired bone anabolic response of PTH in Fgf2 −/− mice on a new genetic background of black swiss/129Sv/FVB/N is similar to the results reported in mice on a black swiss/ 129Sv genetic background [7] . One also needs to note that the dose of PTH treatment in the current study 40 μg/kg for 5×/week for 2 weeks was much lower that the dose used in our previous studies (80 μg/kg once daily for 4 weeks or 160 μg/kg for 10 days). These data further support that the anabolic bone response to PTH requires FGF2.
We previously reported that PTH treatment increased serum FGF2 and increased bone formation markers in osteoporotic patients [5] . In cultured osteoblasts, PTH increased FGF2 and FGF receptor mRNA expression [4] . The increased bone formation stimulated by PTH may be due to increased FGF2, since the ability of PTH to stimulate bone formation is impaired in the absence of endogenous FGF2 [7] . FGF2 positively regulated osteoblast differentiation and bone formation. Disruption of the Fgf2 gene resulted in significantly decreased bone mass and bone formation as revealed by histomorphometry and micro-CT [15, 17] . Decreased osteoblast differentiation might be due to reduced expression of transcription factors, since we found that reduced ATF4 expression in osteoblasts was associated with reduced bone formation in Fgf2 −/− mice [13] . Furthermore, exogenous FGF2 was able to induce ATF4 expression [13] . These results suggest that ATF4 may be a down stream target of FGF2 signaling in osteoblasts (Fig. 4) .
ATF4 is a transcriptional activator for osteoblasts differentiation. Expression of the latest marker of differentiated osteoblasts osteocalcin and synthesis of the major constituent of the bone matrix type I collagen require ATF4 [9] . Atf4 deficient mice display reduced type I collagen synthesis, decreased osteocalcin expression and low bone mass compared to wild type [9] . Therefore, ATF4 is an essential regulator of osteoblast biology. Recent studies demonstrated that ATF4 is critical in the anabolic actions of PTH in bone [11, 12] . PTH increased osteocalcin expression in Atf4 −/− BMSCs was attenuated [12] and PTH stimulated bone formation in Atf4 deficient mice was severely impaired [13] . Thus, PTH signaling in bone is in part mediated by ATF4.
To our knowledge, this is the first report that the impaired bone anabolic response of PTH in the absence of FGF2 is associated with attenuated ATF4 expression. The attenuated ATF4 expression may contribute to reduced osteoblast differentiation with decreased type I collagen and osteocalcin expression and reduced bone formation (Fig. 4) . Future studies will address whether ATF4 over-expression is able to rescue the impaired anabolic actions of PTH on bone formation in Fgf2 knockout mice. PTH is not able to increase ATF4 mRNA expression in the absence of endogenous FGF2 in BMSCs in vitro. ATF4 mRNA expression is significantly reduced in Fgf2 −/− BMSCs compared to Fgf2 +/+ BMSCs at basal level. PTH treatment significantly increased ATF4 mRNA expression in Fgf2 +/+ BMSCs as early as 15 min. However, PTH does not increase ATF4 mRNA expression in Fgf2 −/− BMSCs at the time points examined. Freshly isolated BMSCs from 3 months old male mice were cultured in αMEM with 10% FBS for 6 days, serum deprived 14 h, then treated with 1 nM PTH or vehicle at the indicated times, followed by total RNA extraction for gene analysis. Data are mean ± SEM for two to three independent experiments. female mice were injected subcutaneously 5×/week for two weeks with either vehicle or PTH (40 lg/kg BW) as described in materials and methods. Two days after the last injection, BMD and BMC were determined and total RNA was extracted from whole tibia excluding epiphyses for gene analysis by qPCR. Increased ATF4 mRNA and protein expression in vertebrae tissue by PTH injection is attenuated in Fgf2 −/− mice compared to wild type littermates. 21-23 months old female mice were injected subcutaneously 5×/week for two weeks with either vehicle or PTH (40 μg/kg BW) as described in materials and methods. Two days after the last injection, total RNA was extracted from whole left tibia excluded epiphyses for ATF4 analysis by qPCR (A). (B) Immunohistochemistry for ATF4 protein expression in vertebrae tissue and in osteoblast cells lining on bone surface (arrow) (maganification, 400×). Representative image of vertebrae from each treatment group and genotype are shown. Schematic model -The impaired bone anabolic effect of PTH in Fgf2 knockout mice is associated with reduced ATF4 expression. Anabolic action of PTH on bone formation requires FGF2 and FGF2 increases ATF4 expression and transcriptional activity in osteoblasts. Moreover, ATF4 is a downstream target of PTH signaling in osteoblasts and ATF4 is critical for osteoblasts differentiation. Therefore, attenuated ATF4 expression in Fgf2 −/− mice by PTH injection may contribute to reduced osteoblasts differentiation characterized by decreased osteocalcin and type I collagen expression, which results in impaired stimulation of bone formation by PTH.
